DBT-BIRAC Joint Call: Funding Opportunity for Monoclonal Antibodies (mAbs) under the BioE3 Policy
The Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) invite proposals for funding focused on the development and manufacturing of monoclonal antibodies (mAbs) under the BioE3 (Biotechnology for Economy, Environment & Employment) policy. This initiative aims to promote high-performance, sustainable biomanufacturing and strengthen India’s bioeconomy.
Focus Area: Precision Biotherapeutics – mAbs
Monoclonal antibodies play a vital role in treating infectious diseases, cancer, and autoimmune disorders, especially where vaccines fall short. This call supports innovation in:
-
Discovery & Application-Oriented Research (TRL 3–5): Includes novel mAb discovery, antibody engineering, optimization, and application in diagnostics and therapeutics.
-
Scale-Up & Manufacturing (TRL 5–8): Covers bio-better development, indigenous manufacturing of raw materials, and process optimization for cost-effective mAb production.
Eligibility & Submission for DBT-BIRAC Joint Call
Both Academia and Industry (individually or jointly) can apply. Proposals must:
-
Address clearly defined technological gaps.
-
Indicate current and targeted Technology Readiness Levels (TRL).
-
Comply with regulatory standards and use the prescribed format.
Submission Portals:
-
Academia/ research: www.dbtepromis.nic.in
-
Industry/Collaborations: www.birac.nic.in
Applicants must meet SIRO recognition (for academic institutions) or follow BIRAC guidelines (for companies/LLPs), including Indian ownership criteria.
Funding & Duration of the Research
-
Projects with academic-only partners: Funded by DBT.
-
Academia-Industry or Industry-only: Research Supported by BIRAC.
-
Funding aligned with the “Biomanufacturing and Biofoundry Initiative” plan.
-
Project duration: Up to 2 years, extendable to 5 years.
Deadline
Submit proposals by 16 May 2025.
For queries, contact:
-
Dr. Varshneya Singh (DBT)
-
Dr. Aparna Sharma (BIRAC)
Keywords: monoclonal antibodies funding, DBT BIRAC call for proposals, BioE3 policy India, precision biotherapeutics India, biotechnology funding India, Research, biomanufacturing India, antibody engineering grants, mAb therapeutics India, personalized medicine India, biotech startups India, DBT-BIRAC Joint Call
